Medicare beneficiaries enrolled in Part D prescription drug plans will face a standard deductible of $700 in 2027, up from the current cap. The increase follows the annual indexing formula written into federal law and confirmed by the Centers for Medicare and Medicaid Services in its latest parameter announcement. For the roughly 50 million Americans who rely on Part D coverage, this figure sets the amount they must spend out of pocket on medications before their plan begins paying a share of costs.
Why the $700 Part D deductible changes the math for 2027 enrollees
The deductible is the first financial barrier a Part D enrollee hits each calendar year. Every dollar of that threshold comes directly from a beneficiary’s pocket or, for those who qualify, from federal low-income subsidies that reduce or eliminate cost sharing. A higher deductible means that people who take even moderately priced brand-name drugs could spend weeks or months paying full price before coverage activates. The jump to $700 is not arbitrary. It results from a statutory formula tied to the annual percentage increase in average per-beneficiary drug spending, a mechanism defined in federal Medicare law.
The Inflation Reduction Act restructured Part D benefits starting in 2025, adding a hard cap on annual out-of-pocket costs and shifting more financial risk to insurers and manufacturers. But the IRA did not freeze the deductible. Instead, it preserved the existing indexing method, which means the deductible will keep climbing as long as per-capita drug spending grows. That creates a tension: beneficiaries gained new protections against catastrophic costs while simultaneously watching their upfront exposure rise year over year.
One plausible consequence is that the growing deductible will push more people toward two responses. First, beneficiaries near the income thresholds for federal help may be more likely to apply for low-income subsidies that can zero out the deductible entirely. Second, non-subsidized enrollees shopping during open enrollment may gravitate toward Medicare Advantage plans that bundle drug coverage with lower or zero deductibles, accepting narrower provider networks in exchange for reduced upfront drug costs. Whether those shifts materialize at scale will become visible during the fall 2027 open enrollment period for the 2028 plan year.
CMS documents confirm the $700 threshold and 2027 benefit parameters
The $700 figure appears in the CMS retiree drug subsidy notice for plan years ending in 2027, which also sets related cost thresholds and limits used by employers and union plan sponsors that claim the federal retiree drug subsidy. Although that program operates separately from standard Part D plans, CMS uses the same underlying Part D benefit parameters, making the $700 deductible a reference point across the market.
CMS also outlined the broader 2027 landscape in its 2027 rate announcement for Medicare Advantage and Part D. That fact sheet describes how updated payment benchmarks, risk scores, and Part D benefit parameters interact with the new structure created by the Inflation Reduction Act. The agency highlights how the redesigned catastrophic phase, manufacturer discount obligations, and federal reinsurance payments are expected to influence plan bids and premiums. Within that framework, the $700 deductible functions as one of several levers that determine how costs are shared among beneficiaries, plans, manufacturers, and the federal government.
Additional guidance in a proposed rule for contract year 2027, published for public inspection in the Federal Register docket, addresses policy and technical changes to Medicare Advantage and Part D. While that rulemaking focuses on issues such as plan marketing, utilization management, and quality measures, it situates the deductible increase within a broader set of beneficiary protections. CMS points to the need to balance affordability at the point of sale with the long-term sustainability of the Part D program as drug spending trends continue to evolve.
What the higher deductible means for beneficiaries and plan design
For beneficiaries, the most immediate effect of a $700 deductible is cash flow. People who take only a few low-cost generics may never notice the change, because many plans exempt preferred generics from the deductible. But those who rely on higher-priced brand-name or specialty medications will feel the full impact early in the year, when they must pay the entire negotiated price until the deductible is met. That can be particularly challenging for retirees on fixed incomes who see other household costs, such as housing and food, rising at the same time.
Plan sponsors, meanwhile, must decide how to structure their benefit designs around the new ceiling. Some will likely adopt the full $700 standard deductible to keep premiums lower, shifting more initial risk to enrollees. Others may offer reduced or zero deductibles in exchange for higher monthly premiums or tighter formularies. The new out-of-pocket cap created by the Inflation Reduction Act may also encourage plans to recalibrate cost sharing in the initial coverage and catastrophic phases, since their liability profile has changed.
Looking ahead to 2027, the deductible increase underscores a broader reality of the Part D program: even as policymakers add protections against extreme drug costs, the front-end burden on beneficiaries can still grow. Enrollees and advisors will need to pay close attention to deductible levels, tier structures, and subsidy eligibility when comparing plans, because those details will increasingly determine how affordable prescription drugs feel in everyday life.
